How often should Tinzaparin (dalteparin) be given to a 100kg male with suspected pulmonary embolism if CTPE scan is delayed overnight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tinzaparin Dosing Frequency for Suspected Pulmonary Embolism

Tinzaparin 18,000 units (175 anti-Xa IU/kg for a 100kg patient) should be given once daily by subcutaneous injection while awaiting the delayed CTPE scan. 1

Dosing Rationale

  • For a 100kg male with suspected PE, the appropriate tinzaparin dose is 175 anti-Xa IU/kg once daily, which equals 17,500 units. 1 The 18,000 units already administered is appropriately dosed and should be continued at this same dose once daily. 1

  • Tinzaparin is specifically approved for once-daily administration in the treatment of acute pulmonary embolism. 1, 2, 3 This once-daily regimen has been validated in large randomized controlled trials demonstrating equivalent or superior efficacy compared to continuous intravenous unfractionated heparin. 2, 3

Key Clinical Evidence

  • The THESEE study (612 patients) demonstrated that tinzaparin given once daily subcutaneously was as effective and safe as adjusted-dose intravenous unfractionated heparin for acute PE, with similar rates of recurrent thromboembolism (5.9% vs 7.1%) and major bleeding. 2

  • A subsequent trial showed that once-daily tinzaparin was actually more effective than IV heparin, with 0% recurrent VTE in the tinzaparin group versus 6.8% in the IV heparin group (p=0.01). 3

Practical Management While Awaiting CTPE

  • Continue tinzaparin 18,000 units subcutaneously once daily until the CTPE is performed and results are available. 1 There is no need to split the dose or give it more frequently. 1, 4

  • No laboratory monitoring (aPTT or anti-Xa levels) is required for therapeutic tinzaparin dosing in patients with normal renal function. 1 This is a major advantage over unfractionated heparin. 1, 4

  • Check baseline platelet count before initiating therapy and repeat on day 5, then every 2-3 days if heparin is continued, to monitor for heparin-induced thrombocytopenia. 1

Common Pitfalls to Avoid

  • Do not give tinzaparin twice daily at this dose. 1 The 175 anti-Xa IU/kg regimen is specifically designed for once-daily administration. 1, 2 Twice-daily dosing would result in overdosing and increased bleeding risk.

  • Do not switch to twice-daily dosing based on other LMWH regimens. 1 While enoxaparin can be given either once or twice daily, tinzaparin's pharmacokinetic profile supports once-daily dosing for PE treatment. 1, 4

  • Do not delay anticoagulation waiting for imaging. 1 The guidelines are clear that heparin (or LMWH) should be started immediately when PE is suspected with intermediate or high clinical probability, pending diagnostic confirmation. 1

Duration and Transition

  • Continue tinzaparin for at least 5 days and until oral anticoagulation (warfarin) achieves therapeutic INR (2.0-3.0) for at least 24 hours. 1, 5

  • Warfarin can be started on the same day as tinzaparin once PE is confirmed, with initial dosing of 5-10 mg daily for 2 days. 1, 6

  • If CTPE confirms PE, continue the once-daily tinzaparin regimen without dose adjustment. 1, 2 If PE is excluded, anticoagulation can be discontinued. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.